Home » Stocks » AMTI

Applied Molecular Transport, Inc. (AMTI)

Stock Price: $41.84 USD 1.49 (3.69%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 1.58B
Revenue (ttm) n/a
Net Income (ttm) -66.56M
Shares Out 37.75M
EPS (ttm) -2.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $41.84
Previous Close $40.35
Change ($) 1.49
Change (%) 3.69%
Day's Open 40.93
Day's Range 40.10 - 43.32
Day's Volume 369,383
52-Week Range 17.05 - 78.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the closing of its prev...

1 week ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the pricing of an under...

2 weeks ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has commenced a...

2 weeks ago - GlobeNewsWire

Company continues to strengthen key functions of corporate leadership

3 weeks ago - GlobeNewsWire

Successfully initiated four planned Phase 2 trials for oral AMT-101 with enrollment ongoing

4 weeks ago - GlobeNewsWire

Here's why these highfliers could have more fuel in the tank.

Other stocks mentioned: GRTS, MRNA
1 month ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph....

1 month ago - GlobeNewsWire

Company expands pipeline with second clinical program, AMT-126, an oral IL-22 fusion biologic therapy for diseases associated with intestinal epithelial barrier defects

1 month ago - GlobeNewsWire

About AMTI

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I... [Read more...]

Industry
Biotechnology
IPO Date
Jun 5, 2020
Stock Exchange
NASDAQ
Ticker Symbol
AMTI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for AMTI stock is "Strong Buy." The 12-month stock price forecast is 77.25, which is an increase of 84.63% from the latest price.

Price Target
$77.25
(84.63% upside)
Analyst Consensus: Strong Buy